BioHarvest Sciences (NASDAQ:BHST) Coverage Initiated by Analysts at Maxim Group

Maxim Group assumed coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a report issued on Wednesday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $12.00 price target on the stock.

Separately, HC Wainwright started coverage on shares of BioHarvest Sciences in a report on Friday, December 6th. They set a “buy” rating and a $14.00 price objective on the stock.

BioHarvest Sciences Trading Down 0.8 %

BHST stock traded down $0.05 on Wednesday, reaching $6.15. 241 shares of the company were exchanged, compared to its average volume of 3,549. The firm has a market capitalization of $101.01 million and a P/E ratio of -4.92. BioHarvest Sciences has a 12 month low of $6.15 and a 12 month high of $7.70.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.